RESUMO
BACKGROUND: Normothermic machine perfusion (NMP) is a promising pretransplant kidney quality assessment platform, but it remains crucial to increase its diagnostic potential while ensuring minimal additional injury to the already damaged kidney. Interventions that alter tubular transport can influence renal function and injury during perfusion. This study aimed to determine whether furosemide and desmopressin affect renal function and injury during NMP. METHODS: Eighteen porcine kidneys (n = 6 per group) were subjected to 30 min of warm ischemia and 4 h of oxygenated hypothermic perfusion before being subjected to 6 h of NMP. Each organ was randomized to receive no drug, furosemide (750 mg), or desmopressin (16 µg) during NMP. RESULTS: Compared with the other groups, the addition of furosemide resulted in significantly increased urine output, fractional excretion of sodium and potassium, and urea clearance during NMP. Urinary neutrophil gelatinase-associated lipocalin levels decreased significantly with furosemide supplementation compared with the other groups. The addition of desmopressin did not result in any significantly different outcome measurements compared with the control group. CONCLUSIONS: This study showed that the addition of furosemide affected renal function while attenuating tubulointerstitial injury during NMP. Therefore, furosemide supplementation may provide renal protection and serve as a functional test for pretransplant kidney viability assessment during NMP.
Assuntos
Furosemida , Rim , Preservação de Órgãos , Perfusão , Animais , Furosemida/farmacologia , Suínos , Perfusão/métodos , Rim/efeitos dos fármacos , Rim/patologia , Preservação de Órgãos/métodos , Desamino Arginina Vasopressina/farmacologia , Transplante de Rim , Isquemia Quente/efeitos adversosRESUMO
There is a high degree of uncertainty regarding optimum care of patients with potential or known intake of oral anticoagulants and traumatic brain injury (TBI). Anticoagulation therapy aggravates the risk of intracerebral hemorrhage but, on the other hand, patients take anticoagulants because of an underlying prothrombotic risk, and this could be increased following trauma. Treatment decisions must be taken with due consideration of both these risks. An interdisciplinary group of Austrian experts was convened to develop recommendations for best clinical practice. The aim was to provide pragmatic, clear, and easy-to-follow clinical guidance for coagulation management in adult patients with TBI and potential or known intake of platelet inhibitors, vitamin K antagonists, or non-vitamin K antagonist oral anticoagulants. Diagnosis, coagulation testing, and reversal of anticoagulation were considered as key steps upon presentation. Post-trauma management (prophylaxis for thromboembolism and resumption of long-term anticoagulation therapy) was also explored. The lack of robust evidence on which to base treatment recommendations highlights the need for randomized controlled trials in this setting.
Assuntos
Anticoagulantes/uso terapêutico , Lesões Encefálicas Traumáticas/tratamento farmacológico , Administração Oral , Anticoagulantes/efeitos adversos , Áustria , Lesões Encefálicas Traumáticas/fisiopatologia , Consenso , Dabigatrana/efeitos adversos , Dabigatrana/uso terapêutico , Desamino Arginina Vasopressina/farmacologia , Humanos , Comunicação Interdisciplinar , Tempo de Tromboplastina Parcial/métodos , Pirazóis/análise , Pirazóis/sangue , Pirazóis/uso terapêutico , Piridinas/análise , Piridinas/sangue , Piridinas/uso terapêutico , Piridonas/análise , Piridonas/sangue , Piridonas/uso terapêutico , Rivaroxabana/análise , Rivaroxabana/sangue , Rivaroxabana/uso terapêutico , Tiazóis/análise , Tiazóis/sangue , Tiazóis/uso terapêutico , Tromboembolia/prevenção & controle , Tomografia Computadorizada por Raios X/métodos , Ácido Tranexâmico/uso terapêutico , Resultado do Tratamento , Vitamina K/antagonistas & inibidores , Vitamina K/uso terapêuticoRESUMO
PURPOSE: Control of metastatic spread of colorectal cancer (CRC) remains as a major therapeutic challenge. [V4 Q5 ]dDAVP is a vasopressin peptide analog with previously reported anticancer activity against carcinoma tumors. By acting as a selective agonist of arginine vasopressin type 2 membrane receptor (AVPR2) present in endothelial and tumor cells, [V4Q5]dDAVP is able to impair tumor aggressiveness and distant spread. Our aim was to evaluate the potential therapeutic benefits of [V4Q5]dDAVP on highly aggressive CRC disease using experimental models with translational relevance. MATERIALS AND METHODS: Murine CT-26 and human Colo-205 AVPR2-expressing CRC cell lines were used to test the preclinical efficacy of [V4Q5]dDAVP, both in vitro and in vivo. RESULTS: In syngeneic mice surgically implanted with CT-26 cells in the spleen, sustained intravenous treatment with [V4Q5]dDAVP (0.3 µg/kg) dramatically impaired metastatic progression to liver without overt signs of toxicity, and also reduced experimental lung colonization. The compound inhibited in vivo angiogenesis driven by Colo-205 cells in athymic mice, as well as in vitro endothelial cell migration and capillary tube formation. [V4Q5]dDAVP exerted AVPR2-dependent cytostatic activity in vitro (IC50 1.08 µM) and addition to 5-fluorouracil resulted in synergistic antiproliferative effects both in CT-26 and Colo-205 cells. CONCLUSION: The present preclinical study establishes for the first time the efficacy of [V4Q5]dDAVP on CRC. These encouraging. RESULTS: suggest that the novel second generation vasopressin analog could be used for the management of aggressive CRC as an adjuvant agent during surgery or to complement standard chemotherapy, limiting tumor angiogenesis and metastasis and thus protecting the patient from CRC recurrence.
Assuntos
Inibidores da Angiogênese/farmacologia , Neoplasias Colorretais/tratamento farmacológico , Neoplasias Colorretais/patologia , Desamino Arginina Vasopressina/farmacologia , Neovascularização Patológica/tratamento farmacológico , Inibidores da Angiogênese/uso terapêutico , Animais , Linhagem Celular Tumoral , Proliferação de Células/efeitos dos fármacos , Sobrevivência Celular/efeitos dos fármacos , Desamino Arginina Vasopressina/análogos & derivados , Desamino Arginina Vasopressina/uso terapêutico , Modelos Animais de Doenças , Avaliação Pré-Clínica de Medicamentos , Feminino , Humanos , Neoplasias Hepáticas/diagnóstico , Neoplasias Hepáticas/tratamento farmacológico , Neoplasias Hepáticas/secundário , Neoplasias Pulmonares/diagnóstico , Neoplasias Pulmonares/tratamento farmacológico , Neoplasias Pulmonares/secundário , Camundongos , Metástase Neoplásica , Estadiamento de Neoplasias , Receptores de Vasopressinas/genética , Receptores de Vasopressinas/metabolismo , Ensaios Antitumorais Modelo de XenoenxertoRESUMO
Nocturnal enuresis (NE) is intermittent involuntary voiding during sleep in a child aged 5 years or more. The study was conducted to compare the effect of using laser acupuncture and medication for the treatment of children with nocturnal enuresis (NE) and evaluation of urodynamic parameter after treatment. A randomized study included 45 children ranged from 5 to 15 years presenting with NE. They were randomized into three equal groups-group A, managed with desmopressin acetate; group B, managed with laser acupuncture; and group C, managed with a combination of laser acupuncture and desmopressin-all groups received behavioral therapy. The children were evaluated before and after 3 months of the study to record the efficacy of therapy, side effects and bladder capacity, and 3 months of follow-up after cessation of treatment by bladder diary. A statistically significant higher cure rate was reported in group B patients (73.3 %), while in groups A and C, improvement was reported in 20.0 and 13.3 %, respectively (p value = 0.002). Laser acupuncture is noninvasive, painless tool, with no side effects and lower recurrence rate which can be considered as an alternative therapy for patients with NE.
Assuntos
Terapia por Acupuntura , Lasers , Enurese Noturna/terapia , Adolescente , Criança , Pré-Escolar , Desamino Arginina Vasopressina/farmacologia , Desamino Arginina Vasopressina/uso terapêutico , Feminino , Humanos , Masculino , Enurese Noturna/tratamento farmacológico , Recidiva , Bexiga Urinária/efeitos dos fármacos , Bexiga Urinária/fisiopatologiaRESUMO
The role of subtypes of vasopressin receptors in modulation of renal sodium reabsorption was studied in in vivo experiments on Wistar rats. Selective V1a receptor agonist reduced sodium reabsorption in the kidneys and expression of these receptors increased by practically 100 times. This effect was similar to the effect of furosemide. Selective V2 receptor agonist enhanced sodium reabsorption in the kidney and simultaneously increased reabsorption of solute-free water. Stimulation of V1b receptors did not affect sodium transport. Our findings attest to the key role of V1a receptors in the regulation of renal excretion of sodium ions.
Assuntos
Desamino Arginina Vasopressina/farmacologia , Diuréticos/farmacologia , Furosemida/farmacologia , Receptores de Vasopressinas/agonistas , Sódio/metabolismo , Animais , Transporte Biológico , Avaliação Pré-Clínica de Medicamentos , Feminino , Rim/efeitos dos fármacos , Rim/metabolismo , Ratos WistarRESUMO
The apelinergic system, comprised of apelin and its G protein-coupled receptor (APJ; APLNR as given in MGI Database), is expressed within key regions of the central nervous system associated with arginine vasopressin (AVP) synthesis and release as well as in structures involved in the control of drinking behaviour, including the magnocellular neurones of the hypothalamus, circumventricular organs, and the pituitary gland. This localisation is indicative of a possible functional role in fluid homeostasis. We investigated a role for APJ in the regulation of fluid balance using mice deficient for the receptor. Male APJ wild-type and knockout (APJ(-/-)) mice were housed in metabolic cages to allow determination of water intake and urine volume and osmolality. When provided with free access to water, APJ(-/-) mice drank significantly less than wild-types, while their urine volume and osmolality did not differ. Water deprivation for 24 h significantly reduced urine volume and increased osmolality in wild-type but not in APJ(-/-) mice. Baseline plasma AVP concentration increased comparably in both wild-type and APJ(-/-) mice following dehydration; however, APJ(-/-) mice were unable to concentrate their urine to the same extent as wild-type mice in response to the V2 agonist desmopressin. Analysis of c-fos (Fos as given in MGI Database) mRNA expression in response to dehydration showed attenuation of expression within the subfornical organ, accentuated expression in the paraventricular nucleus, but no differences in expression in the supraoptic nucleus nor median pre-optic nucleus in APJ(-/-) mice compared with wild-type. These findings demonstrate a physiological role for APJ in mechanisms of water intake and fluid retention and suggest an anti-diuretic effect of apelin in vivo.
Assuntos
Proteínas de Transporte/metabolismo , Homeostase/fisiologia , Hipotálamo/fisiologia , Receptores Acoplados a Proteínas G/genética , Receptores Acoplados a Proteínas G/metabolismo , Equilíbrio Hidroeletrolítico/fisiologia , Adipocinas , Animais , Antidiuréticos/farmacologia , Apelina , Receptores de Apelina , Arginina Vasopressina/sangue , Arginina Vasopressina/genética , Líquidos Corporais/fisiologia , Desamino Arginina Vasopressina/farmacologia , Ingestão de Líquidos/fisiologia , Feminino , Genótipo , Homeostase/efeitos dos fármacos , Peptídeos e Proteínas de Sinalização Intercelular , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Knockout , Concentração Osmolar , Gravidez , Urina , Privação de Água/fisiologia , Equilíbrio Hidroeletrolítico/efeitos dos fármacosRESUMO
It has been argued that hyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis is a major biological abnormality in patients suffering from psychiatric conditions such as major depression. Both arginine vasopressin (AVP) and corticotrophin releasing factor (CRF) are responsible for stimulating the release of adrenocorticotropic hormone (ACTH) from the anterior pituitary. CRF is thought to be the predominant secretagogue under normal conditions but AVP may play a more important role in situations of aberrant/chronic stress. Studies in patients suffering from melancholic depression indicate a hyper-responsiveness to agonism at the vasopressin receptor type 1B (V(1B)); patients display a heightened ACTH release after challenge with the mixed V(1B)/V(2) (vasopressin receptor type 2) agonist desmopressin in comparison to control subjects. A V(1B) antagonist has been developed which has significant selectivity for the human V(1B) receptor over the other members of the vasopressin receptor sub-family. The compound acts as an effective antagonist at both the human recombinant receptor (stably expressed in Chinese hamster ovary (CHO) cells) and the native rat V(1B) receptor (using isolated anterior pituitary cells), blocking the induction of luciferase and the release of ACTH, respectively. In vivo the compound can block the release of ACTH after challenge with a variety of V(1B) agonists. It can also attenuate the ACTH response to acute stressors in rats. Interestingly, this compound does not modulate the activity of the HPA axis under normal basal conditions.
Assuntos
Antagonistas dos Receptores de Hormônios Antidiuréticos , Transtornos do Humor/tratamento farmacológico , Hormônio Adrenocorticotrópico/sangue , Animais , Arginina Vasopressina/fisiologia , Arginina Vasopressina/uso terapêutico , Células CHO , Hormônio Liberador da Corticotropina/farmacologia , Hormônio Liberador da Corticotropina/fisiologia , Cricetinae , Cricetulus , Desamino Arginina Vasopressina/farmacologia , Transtorno Depressivo/tratamento farmacológico , Transtorno Depressivo/fisiopatologia , Humanos , Sistema Hipotálamo-Hipofisário/efeitos dos fármacos , Hipotálamo/efeitos dos fármacos , Hipotálamo/fisiopatologia , Masculino , Adeno-Hipófise/efeitos dos fármacos , Adeno-Hipófise/fisiopatologia , Transtornos Psicóticos/tratamento farmacológico , Transtornos Psicóticos/fisiopatologia , Ratos , Ratos Sprague-Dawley , Receptores de Vasopressinas/efeitos dos fármacos , Receptores de Vasopressinas/fisiologia , Inibidores Seletivos de Recaptação de Serotonina/uso terapêuticoRESUMO
OBJECTIVE: To test the hypothesis that 1-desamino-8-D-arginine vasopressin (dDAVP) has an effect on prepulse inhibition (PPI) of startle in patients with primary monosymptomatic enuresis (PME), thus indicating a central effect. STUDY DESIGN: Patients with PME (n = 21, age 6 to 12 years) were enrolled in a prospective, randomized, double-blinded, cross-over study. Startle reflexes and PPI were measured under dDAVP treatment versus placebo. RESULTS: The data show that dDAVP has a significant effect on PPI, raising it from 38.88% under placebo to the age-related normal level of 62.6% with dDAVP treatment (P = .0127). CONCLUSIONS: Our findings revive the concept of a central pathophysiology of PME and offer a different explanation for the effects of dDAVP, which not only acts on the kidney, but also is (as is AVP) a central neurotransmitter with a signal cascade on relevant reflex mechanisms.
Assuntos
Desamino Arginina Vasopressina/farmacologia , Inibição Neural/efeitos dos fármacos , Enurese Noturna/fisiopatologia , Reflexo de Sobressalto/efeitos dos fármacos , Estimulação Acústica , Criança , Estudos Cross-Over , Desamino Arginina Vasopressina/uso terapêutico , Método Duplo-Cego , Eletromiografia , Feminino , Humanos , Masculino , Enurese Noturna/tratamento farmacológico , Enurese Noturna/etiologia , Reflexo de Sobressalto/fisiologiaRESUMO
In renal epithelia, vasopressin influences salt and water transport, chiefly via vasopressin V(2) receptors (V(2)Rs) linked to adenylyl cyclase. A combination of vasopressin-induced effects along several distinct portions of the nephron and collecting duct system may help balance the net effects of antidiuresis in cortex and medulla. Previous studies of the intrarenal distribution of V(2)Rs have been inconclusive with respect to segment- and cell-type-related V(2)R expression. Our study therefore aimed to present a high-resolution analysis of V(2)R mRNA expression in rat, mouse, and human kidney epithelia, supplemented with immunohistochemical data. Cell types of the renal tubule were identified histochemically using specific markers. Pronounced V(2)R signal in thick ascending limb (TAL) was corroborated functionally; phosphorylation of Na(+)-K(+)-2Cl(-) cotransporter type 2 (NKCC2) was established in cultured TAL cells from rabbit and in rats with diabetes insipidus that were treated with the V(2)R agonist desmopressin. We found solid expression of V(2)R mRNA in medullary TAL (MTAL), macula densa, connecting tubule, and cortical and medullary collecting duct and weaker expression in cortical TAL and distal convoluted tubule in all three species. Additional V(2)R immunostaining of kidneys and rabbit TAL cells confirmed our findings. In agreement with strong V(2)R expression in MTAL, kidneys from rats with diabetes insipidus and cultured TAL cells revealed sharp, selective increases in NKCC2 phosphorylation upon desmopressin treatment. Macula densa cells constitutively showed strong NKCC2 phosphorylation. Results suggest comparably significant effects of vasopressin-induced V(2)R signaling in MTAL and in connecting tubule/collecting duct principal cells across the three species. Strong V(2)R expression in macula densa may be related to tubulovascular signal transfer.
Assuntos
Células Epiteliais/metabolismo , Medula Renal/metabolismo , Alça do Néfron/metabolismo , Receptores de Vasopressinas/metabolismo , Adenilil Ciclases/metabolismo , Animais , Antidiuréticos/farmacologia , Células Cultivadas , Desamino Arginina Vasopressina/farmacologia , Humanos , Córtex Renal/citologia , Córtex Renal/metabolismo , Medula Renal/citologia , Túbulos Renais Coletores/citologia , Túbulos Renais Coletores/metabolismo , Alça do Néfron/citologia , Masculino , Camundongos , Camundongos Endogâmicos C57BL , RNA Mensageiro/metabolismo , Distribuição Aleatória , Ratos , Ratos Brattleboro , Ratos Wistar , Simportadores de Cloreto de Sódio-Potássio/metabolismo , Membro 1 da Família 12 de Carreador de SolutoRESUMO
We previously reported that vasopressin deficient Brattleboro (BRAT) rats exhibit deficits in prepulse inhibition (PPI) of the startle reflex that are consistent with PPI deficits exhibited by patients with schizophrenia and other neuropsychiatric disorders. Preliminary evidence indicates that this may be the basis of a predictive model for antipsychotic drug efficacy. Here we report the effects of acute and chronic administration of established and putative antipsychotics on these PPI deficits. BRAT rats, compared to their derivative strain, Long Evans rats, exhibited significantly decreased PPI and startle habituation consistent with patients with schizophrenia and other neuropsychiatric disorders. The second generation antipsychotics, risperidone and clozapine as well as a neurotensin agonist (PD149163) increased BRAT rat PPI, whereas saline, the typical antipsychotic, haloperidol, and a vasopressin analog (1-desamino-D-arginine vasopressin) did not. Similar to their effects in humans, chronic administration of antipsychotic drugs produced stronger effects than acute administration. These results further support the BRAT rat as a model of sensorimotor gating deficits with predictive validity for antipsychotics. The model appears to be able to differentiate first generation from second generation antipsychotics, identify putative antipsychotics with novel mechanisms (i.e., peptides) and reasonably model the therapeutic time course of antipsychotic drugs in humans.
Assuntos
Antipsicóticos/farmacologia , Arginina Vasopressina/fisiologia , Inibição Neural/efeitos dos fármacos , Reflexo de Sobressalto/efeitos dos fármacos , Esquizofrenia/tratamento farmacológico , Análise de Variância , Animais , Arginina Vasopressina/análogos & derivados , Arginina Vasopressina/deficiência , Arginina Vasopressina/genética , Clozapina/farmacologia , Desamino Arginina Vasopressina/farmacologia , Modelos Animais de Doenças , Esquema de Medicação , Avaliação Pré-Clínica de Medicamentos/métodos , Habituação Psicofisiológica/efeitos dos fármacos , Haloperidol/farmacologia , Neurotensina/análogos & derivados , Neurotensina/farmacologia , Ratos , Ratos Brattleboro , Ratos Long-Evans , Ratos Mutantes , Risperidona/farmacologia , Esquizofrenia/fisiopatologia , Estatísticas não ParamétricasRESUMO
Abnormalities of micturition occur in many different diseases, have a variety of causes and take several forms. This review will focus exclusively on those abnormalities in which antidiuretic therapy may be of benefit. These conditions are primarily characterized by an increase in the total amount of urine produced (polyuria) or a circadian shift in the control of urine production and/or voiding (nocturnal enuresis, nocturia).
Assuntos
Antidiuréticos/uso terapêutico , Enurese Noturna/tratamento farmacológico , Poliúria/tratamento farmacológico , Antidiuréticos/farmacologia , Desamino Arginina Vasopressina/farmacologia , Desamino Arginina Vasopressina/uso terapêutico , Humanos , Enurese Noturna/fisiopatologia , Poliúria/fisiopatologia , Qualidade de Vida , Transtornos Urinários/tratamento farmacológico , Transtornos Urinários/fisiopatologia , Água/metabolismoRESUMO
The purpose of the present studies was to determine the effects of high-dose aldosterone and dDAVP treatment on renal aquaporin-2 (AQP2) regulation and urinary concentration. Rats were treated for 6 days with either vehicle (CON; n = 8), dDAVP (0.5 ng/h, dDAVP, n = 10), aldosterone (Aldo, 150 microg/day, n = 10) or combined dDAVP and aldosterone treatment (dDAVP+Aldo, n = 10) and had free access to water with a fixed food intake. Aldosterone treatment induced hypokalemia, decreased urine osmolality, and increased the urine volume and water intake in ALDO compared with CON and dDAVP+Aldo compared with dDAVP. Immunohistochemistry and semiquantitative laser confocal microscopy revealed a distinct increase in basolateral domain AQP2 labeling in cortical collecting duct (CCD) principal cells and a reduction in apical domain labeling in Aldo compared with CON rats. Given the presence of hypokalemia in aldosterone-treated rats, we studied dietary-induced hypokalemia in rats, which also reduced apical AQP2 expression in the CCD but did not induce any increase in basolateral AQP2 expression in the CCD as observed with aldosterone treatment. The aldosterone-induced basolateral AQP2 expression in the CCD was thus independent of hypokalemia but was dependent on the presence of sodium and aldosterone. This redistribution was clearly blocked by mineralocorticoid receptor blockade. The increased basolateral expression of AQP2 induced by aldosterone may play a significant role in water metabolism in conditions with increased sodium reabsorption in the CCD.
Assuntos
Aldosterona/farmacologia , Aquaporina 2/biossíntese , Córtex Renal/metabolismo , Túbulos Renais Coletores/metabolismo , Angiotensina II/sangue , Animais , Desamino Arginina Vasopressina/farmacologia , Ingestão de Líquidos/efeitos dos fármacos , Ingestão de Líquidos/fisiologia , Ingestão de Alimentos/efeitos dos fármacos , Ingestão de Alimentos/fisiologia , Homeostase/efeitos dos fármacos , Hipopotassemia/metabolismo , Immunoblotting , Imuno-Histoquímica , Córtex Renal/efeitos dos fármacos , Túbulos Renais Coletores/efeitos dos fármacos , Masculino , Microscopia Imunoeletrônica , Fosforilação , Deficiência de Potássio/metabolismo , Ratos , Ratos Sprague-Dawley , Ratos Wistar , Fármacos Renais/farmacologia , Serina/metabolismo , Frações Subcelulares/efeitos dos fármacos , Frações Subcelulares/metabolismo , Água/metabolismoRESUMO
Activation of P2Y2 receptor (P2Y2-R) in inner medullary collecting duct (IMCD) of rat decreases AVP-induced water flow and releases PGE(2). We observed that dehydration of rats decreases the expression of P2Y2 receptor in inner medulla (IM) and P2Y2-R-mediated PGE(2) release by IMCD. Because circulating vasopressin (AVP) levels are increased in dehydrated condition, we examined whether chronic infusion of desmopressin (dDAVP) has a similar effect on the expression and activity of P2Y2-R. Groups of rats were infused with saline or dDAVP (5 or 20 ng/h sc, 5 or 6 days) via osmotic minipumps and euthanized. Urine volume, osmolality, and PGE(2) metabolite content were determined. AQP2- and P2Y2- and V2-R mRNA and/or protein in IM were quantified by real-time RT-PCR and immunoblotting, respectively. P2Y2-R-mediated PGE(2) release by freshly prepared IMCD was assayed using ATPgammaS as a ligand. Chronic dDAVP infusion resulted in low-output of concentrated urine and significantly increased the AQP2 protein abundance in IM. On the contrary, dDAVP infusion at 5 or 20 ng/h significantly decreased P2Y2-R protein abundance (approximately 40% of saline-treated group). In parallel, the relative expression of P2Y2-R vs. AQP2- or V2-R mRNA was significantly decreased. Furthermore, the P2Y2-R-mediated PGE(2) release by IMCD was significantly decreased in rats infused 20 ng/h but not 5 ng/h of dDAVP. Urinary PGE(2) metabolite excretion, however, did not change with dDAVP infusion. In conclusion, chronic dDAVP infusion decreases the expression and activity of P2Y2-R in IM. This may be due to a direct effect of dDAVP or dDAVP-induced increase in medullary tonicity.
Assuntos
Desamino Arginina Vasopressina/farmacologia , Dinoprostona/metabolismo , Medula Renal/metabolismo , Túbulos Renais Coletores/metabolismo , Antagonistas do Receptor Purinérgico P2 , Receptores Purinérgicos P2/biossíntese , Fármacos Renais/farmacologia , Trifosfato de Adenosina/análogos & derivados , Trifosfato de Adenosina/farmacologia , Animais , Aquaporina 2 , Aquaporinas/metabolismo , Western Blotting , Primers do DNA , DNA Complementar/biossíntese , Desamino Arginina Vasopressina/administração & dosagem , Infusões Intravenosas , Medula Renal/efeitos dos fármacos , Túbulos Renais Coletores/citologia , Túbulos Renais Coletores/efeitos dos fármacos , Masculino , Ratos , Ratos Sprague-Dawley , Receptores Purinérgicos P2/metabolismo , Receptores Purinérgicos P2Y2 , Fármacos Renais/administração & dosagem , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Urodinâmica/efeitos dos fármacosRESUMO
La hemorragia uterina disfuncional es un transtorno frecuente ginecológico. Es un diagnóstico de exclusión, y el clínico debe proceder a una evaluación lógica y escalonada de todas las causas de sangrado anormal. La menorragia en la mayoría de los casos se asocia con anovulación. El tratamiento médico debería ser la primera opción terapéutica y puede ser dividido en terapia no hormonal y hormonal. Los dos principales tratamientos para la menorragia asociada a ciclos ovulatorios son no hormonales, mediante un antifibrinolítico como el ácido tranexámico y antiinflamatorios. Tradicionalmente la terapia hormonal para la menorragia ha estado constituida por los progestágenos y los anticonceptivos orales. El sistema intrauterino de liberación de levonorgestrel ofrece un nuevo concepto terapéutico que combina una eficaz contracepción con una reducción del sangrado menstrual. Es una buena alternativa conservadora a la resección endometrial y parece ser una importante alternativa a la medicación oral. En el manejo de la pérdida menstrual excesiva hay una evidencia demostrada de que muchos médicos no prescriben los tratamientos más adecuados. El incremento en la utilización de tratamientos efectivos mejoraría las expectativas de las pacientes y supondría una alternativa a la cirugía (AU)
Assuntos
Feminino , Humanos , Hemorragia Uterina/tratamento farmacológico , Anticoncepcionais Orais Combinados/farmacologia , Anti-Inflamatórios não Esteroides/farmacologia , Hemorragia Uterina/diagnóstico , Anovulação/complicações , Menorragia/etiologia , Antifibrinolíticos/farmacologia , Ácido Tranexâmico/farmacologia , Levanogestrel/farmacologia , Danazol/farmacologia , Medicina Herbária , Ferro/farmacologia , Etamsilato/farmacologia , Hormônio Liberador de Gonadotropina/farmacologia , Desamino Arginina Vasopressina/farmacologiaRESUMO
Recombinant human interleukin-11 (rhIL-11), a glycoprotein 130 (gp130)-signaling cytokine approved for treatment of thrombocytopenia, also raises von Willebrand factor (VWF) and factor VIII (FVIII) by an unknown mechanism. Desmopressin (1-deamino-8-d-arginine vasopressin [DDAVP]) releases stored VWF and FVIII and is used for treatment of VWF and FVIII deficiencies. To compare the effect of these 2 agents, heterozygous von Willebrand disease (VWD) and normal dogs were treated with either rhIL-11 (50 microg/kg/d subcutaneously x 7 days) or DDAVP (5 microg/kg/d intravenously x 7 days). The rhIL-11 produced a gradual and sustained elevation of VWF and FVIII levels in both heterozygous VWD and normal dogs while DDAVP produced a rapid and unsustained increase. Importantly, rhIL-11 treatment produced a 2.5- to 11-fold increase in VWF mRNA in normal canine heart, aorta, and spleen but not in homozygous VWD dogs, thus identifying a mechanism for elevation of plasma VWF in vivo. Moreover, dogs pretreated with rhIL-11 retain a DDAVP-releasable pool of VWF and FVIII, suggesting that rhIL-11 does not significantly alter trafficking of these proteins to or from storage pools. The half-life of infused VWF is unchanged by rhIL-11 in homozygous VWD dogs. These results show that rhIL-11 and DDAVP raise plasma VWF by different mechanisms. Treatment with rhIL-11 with or without DDAVP may provide an alternative to plasma-derived products for some VWD and hemophilia A patients if it is shown safe in clinical trials.
Assuntos
Desamino Arginina Vasopressina/uso terapêutico , Interleucina-11/uso terapêutico , RNA Mensageiro/biossíntese , Corpos de Weibel-Palade/metabolismo , Doenças de von Willebrand/fisiopatologia , Fator de von Willebrand/metabolismo , Animais , Aorta/efeitos dos fármacos , Aorta/metabolismo , Desamino Arginina Vasopressina/farmacologia , Cães , Avaliação Pré-Clínica de Medicamentos , Fator VIII/metabolismo , Meia-Vida , Coração/efeitos dos fármacos , Heterozigoto , Interleucina-11/farmacologia , Miocárdio/metabolismo , RNA Mensageiro/genética , Proteínas Recombinantes/farmacologia , Proteínas Recombinantes/uso terapêutico , Baço/efeitos dos fármacos , Baço/metabolismo , Corpos de Weibel-Palade/efeitos dos fármacos , Doenças de von Willebrand/tratamento farmacológico , Doenças de von Willebrand/genética , Fator de von Willebrand/biossíntese , Fator de von Willebrand/genéticaRESUMO
The renal excretion of selenium was investigated in ewes with an excretion of hypotonic urine (control group) and in ewes with a formation of highly concentrated urine. Chronic stimulation of the urinary concentrating activity of sheep kidneys was induced by a long-term treatment with 1-desamino-8-D-arginine vasopressin (dDAVP), a synthetic analogue of vasopressin with prolonged effects. Young animals with 22 to 25 kg b.w. were fed a normal protein diet providing a daily intake of 129.25 g of crude protein, 12.03 MJ of digestible energy and 0.18 mg of selenium for 3 weeks. The vasopressin treated sheep (n = 11) were given subcutaneous injections of 12.5 micrograms of dDAVP in glycerol twice daily for one week before the clearance measurement of renal functions. The control group (n = 11) was treated with glycerol only. The administration of dDAVP resulted in a highly significant decrease of the urinary flow rate (from 3.19 +/- 0.50 in control group to 0.33 +/- 0.03 mL.min-1 in dDAVP animals, P < 0.001) without changes in the glomerular filtration rate (80.18 +/- 6.36 in controls vs. 77.86 +/- 6.26 mL.min-1, NS). No effects on plasma selenium level were observed (0.17 +/- 0.03 in controls vs. 0.20 +/- 0.03 mumol.L-1, NS) but the amounts of selenium excreted were found to be highly significantly reduced (from 0.29 +/- 0.05 in controls to 0.03 +/- 0.01 nmol.min-1, P < 0.001) in dDAVP treated sheep. Despite a large reduction in urinary flow rate, the selenium concentration in urine was actually the same in both groups (0.09 +/- 0.01 mumol.L-1) resulting in a sharp fall in the renal clearance of selenium (2.20 +/- 0.54 in controls vs. 0.18 +/- 0.03 mL.min-1, P < 0.01) due to dDAVP. This seems to be a consequence of the large increase in the selenium solvent drag induced by a vasopressin treatment. The results presented suggest that vasopressin may contribute to maintenance of the selenium balance in sheep via its effects on renal function.
Assuntos
Desamino Arginina Vasopressina/farmacologia , Rim/efeitos dos fármacos , Fármacos Renais/farmacologia , Selênio/urina , Ovinos/metabolismo , Animais , Proteínas Alimentares/administração & dosagem , Feminino , Taxa de Filtração Glomerular/veterinária , Rim/fisiologia , Selênio/metabolismo , Ovinos/urina , Fatores de Tempo , Equilíbrio Hidroeletrolítico/efeitos dos fármacosRESUMO
Galanin (GAL) is a neuropeptide cosynthesized with vasopressin (AVP) in neurons of the hypothalamo-neurohypophysial system. It increases food intake when injected into the brain and elicits an overconsumption of fat. The Brattleboro rat (DI) is genetically unable to produce AVP; the AVP-deficient-producing neurons of the hypothalamo-neurohypophysial system of DI rats are chronically stimulated and DI rats suffer from diabetes insipidus. We studied the central expression of GAL and the dietary preferences in the DI rat. GAL was overexpressed in the hypothalamus of the DI rat. GAL mRNA was higher by 1.8-fold in the supraoptic (P < 0.05) and by four-fold in the paraventricular nuclei (P < 0.001) of male and female DI rats compared with those of control Long Evans (LE) rats. However, GAL mRNA was lower in the arcuate nuclei of DI rats and equal to that of LE rats in the dorsomedian nuclei. We also measured a high preference for a lipid diet (45% of the daily consumption) when DI rats ate from a choice of the three macronutrients. Chronic infusion with deamino-8D-AVP (agonist of AVP V2 receptors) prevented the diabetes insipidus and the chronic stimulation of the hypothalamo-neurohypophysial system of the DI rats. However, the treatment did not suppress the overexpression of GAL, nor did it affect the rats' preference for a lipid diet. We conclude that the DI rat provides a novel animal model in which a spontaneous dietary preference correlates with the overexpression of one of the hypothalamic peptides, GAL.
Assuntos
Preferências Alimentares/fisiologia , Galanina/biossíntese , Galanina/fisiologia , Hipotálamo/metabolismo , Animais , Água Corporal/metabolismo , Desamino Arginina Vasopressina/farmacologia , Carboidratos da Dieta/administração & dosagem , Gorduras na Dieta/administração & dosagem , Proteínas Alimentares/administração & dosagem , Ingestão de Líquidos/efeitos dos fármacos , Feminino , Imunoquímica , Hibridização In Situ , Masculino , Neuropeptídeos/biossíntese , Ratos , Ratos BrattleboroRESUMO
GH secretagogues (GHSs) act via specific receptors in the hypothalamus and the pituitary gland to release GH. GHSs also stimulate the hypothalamo-pituitary-adrenal (HPA) axis via central mechanisms probably involving CRH or arginine vasopressin (AVP). We studied the effects of hexarelin, CRH, and desmopressin, an AVP analog, on the stimulation of the HPA axis in 15 healthy young male volunteers. Circulating ACTH, cortisol, GH and PRL concentrations were measured for 2 h after the injection of hexarelin, CRH, or desmopressin alone and the combination of hexarelin plus CRH or hexarelin plus desmopressin. Symptoms during the tests were assessed by visual analog scales. Hexarelin significantly increased ACTH and cortisol release (area under the curve, 3,444+/-696 ng/L x 125 min and 45,844+/-2,925 nmol/L x 125 min, respectively), and this effect was augmented by the addition of CRH in a dose that on its own produces maximal stimulation (6,580+/-1,572 ng/mL x 125 min and 63,170+/-2,616 nmol/L x 125 min; P = 0.01 and 0.001, respectively), but was not influenced by the addition of desmopressin (3,540+/-852 ng/mL x 125 min and 35,319+/-3,252 nmol/L x 125 min; not significant). CRH on its own caused similar or slightly higher ACTH and cortisol release than hexarelin alone. Desmopressin given alone elicited a rapid rise in circulating ACTH and cortisol, but its effects were less than those of any other treatment and were not augmented by hexarelin. Hexarelin also caused significant GH and PRL release, but these effects were not influenced by the coadministration of CRH or desmopressin. Visual analog scales showed an acute small increment in appetite with hexarelin. Our data suggest that the effect of GHSs on the HPA axis involve at least in part the stimulation of AVP release. In summary, we have shown that in healthy male volunteers, the effect of hexarelin on the HPA axis does not involve CRH, but may occur through the stimulation of AVP release.
Assuntos
Glândulas Suprarrenais/efeitos dos fármacos , Arginina Vasopressina/metabolismo , Substâncias de Crescimento/farmacologia , Hipotálamo/efeitos dos fármacos , Oligopeptídeos/farmacologia , Hipófise/efeitos dos fármacos , Glândulas Suprarrenais/metabolismo , Hormônio Adrenocorticotrópico/metabolismo , Adulto , Hormônio Liberador da Corticotropina/farmacologia , Desamino Arginina Vasopressina/farmacologia , Método Duplo-Cego , Hormônio do Crescimento Humano/metabolismo , Humanos , Hidrocortisona/metabolismo , Hipotálamo/metabolismo , Masculino , Hipófise/metabolismo , Prolactina/metabolismoRESUMO
Increased plasma osmolality results in increased central as well as peripheral release of vasopressin. Experiments were carried out to determine whether, in this circumstance, vasopressin can act centrally to modulate its peripheral release. Prior to the start of a thirty-min i.v. infusion of 2.5 M or 0.15 M NaCl, the rats were given an intracerebroventricular (i.c.v.) injection of a peptide V1/V2 vasopressin antagonist (2 micrograms), OPC-31260 (60 micrograms), a non-peptide V2 antagonist, or 1-desamino-8-D-arginine vasopressin (dDAVP, 5 ng), a V2 agonist. Experiments with the peptide antagonist were carried out in male and non-estrous female rats. Since there were no differences between males and females in the measured responses, experiments with the other two drugs were carried out only in males. Pretreatment with either the V1/V2 antagonist or the V2 antagonist enhanced the increase in plasma vasopressin levels in response to the hypertonic saline infusion by about 50% at the end of 30 min. dDAVP, on the other hand, had no effect. None of the i.c.v. drugs had an affect on either the pressor or bradycardic responses to hypertonic saline infusion. These observations suggest that vasopressin can act centrally in a negative feedback fashion to attenuate its own release into the peripheral circulation in response to increased plasma osmolality.
Assuntos
Antagonistas dos Receptores de Hormônios Antidiuréticos , Benzazepinas/farmacologia , Desamino Arginina Vasopressina/farmacologia , Caracteres Sexuais , Vasopressinas/metabolismo , Animais , Arginina Vasopressina/análogos & derivados , Arginina Vasopressina/farmacologia , Avaliação Pré-Clínica de Medicamentos , Retroalimentação , Feminino , Antagonistas de Hormônios/farmacologia , Injeções Intraventriculares , Masculino , Concentração Osmolar , Ratos , Ratos Sprague-Dawley , Receptores de Vasopressinas/agonistas , Cloreto de Sódio/farmacologiaRESUMO
Arginine vasopressin (AVP) and oxytocin (OT) mRNAs are targeted to the axonal compartment of rat hypothalamic magnocellular neurons. Salt-loading results in a considerable rise in hypothalamic and axonal AVP mRNA but only a moderate increase for axonal OT mRNA. Here we report that hypoosmolality gives rise to a rapid decrease of axonal AVP encoding transcripts to undetectable levels after 2 weeks. The levels of OT mRNA in the axonal compartment did not change significantly. In the hypothalamus the mRNA for AVP also decreased. The size of the poly(A) tract of AVP encoding transcripts appeared to be strictly correlated with plasma osmolality. In contrast, the amount and size of OT encoding mRNAs were only moderately or not influenced by hypoosmolar stimuli.